Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants

Journal of Virology

Volumn 77, Issue 21, 2003, Pages 11588-11595

  Hann, Byron ^a,b   Balmain, Allan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; ONYX 015; PROTEIN P53; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CELL SPECIFICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN DNA BINDING; RESPIRATORY EPITHELIUM; TARGET CELL DESTRUCTION; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ADENOVIRUSES, HUMAN; BRONCHI; CELLS, CULTURED; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0142092408     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.21.11588-11595.2003     Document Type: Article

References (50)

1. Barker, D. D., and A. J. Berk. 1987. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-121.
2. Bates, S., and K. H. Vousden. 1996. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:12-18.
3. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
4. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
5. Delmolino, L., H. Band, and V. Band. 1993. Expression and stability of p53 protein in normal human mammary epithelial cells. Carcinogenesis 14:827-832.
6. Di Como, C. J., C. Gaiddon, and C. Prives. 1999. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1438-1449.
7. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. K. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42-46.
8. El-Hizawi, S., J. P. Lagowski, M. Kulesz-Martin, and A. Albor. 2002. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res. 62:3264-3270.
9. Eliyahu, D., D. Michalovitz, and M. Oren. 1985. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158-160.
10. Gadbois, D. M., and B. E. Lehnert. 1997. Cell cycle response to DNA damage differs in bronchial epithelial cells and lung fibroblasts. Cancer Res. 57:3174-3179.
11. Gaiddon, C., M. Lokshin, J. Ahn, T. Zhang, and C. Prives. 2001. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:1874-1887.
12. Ganly, I., Y. T. Kim, B. Hann, A. Balmain, and R. Brown. 2001. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther. 8:369-375.
13. Girinsky, T., C. Koumenis, T. G. Graeber, D. M. Peehl, and A. J. Giaccia. 1995. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 55:3726-3731.
14. Glotzer, J. B., M. Saltik, S. Chiocca, A. I. Michou, P. Moseley, and M. Cotten. 2000. Activation of heat-shock response by an adenovirus is essential for virus replication. Nature 407:207-211.
15. Gobert, C., A. Skladanowski, and A. K. Larsen. 1999. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc. Natl. Acad. Sci. USA 96:10355-10360.
16. Goodrum, F. D., and D. A. Ornelles. 1997. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71:548-561.
17. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:9479-9490.
18. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
19. Gualberto, A., K. Aldape, K. Kozakiewicz, and T. D. Tlsty. 1998. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95:5166-5171.
20. Hall, A. R., B. R. Dix, S. J. O'Carroll, and A. W. Braithwaite. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1068-1072.
21. Harada, J. N., and A. J. Berk. 1999. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73:5333-5344.
22. Heise, C., A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:639-645.
23. Ho, Y. S., R. Galos, and J. Williams. 1982. Isolation of type 5 adenovirus mutants with a cold-sensitive host range phenotype: genetic evidence of an adenovirus transformation maintenance function. Virology 122:109-124.
24. Hollstein, M., B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano, and C. C. Harris. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24:141-146.
25. Johnson, L., A. Shen, L. Boyle, J. Kunich, K. Pandey, M. Lemmon, T. Hermiston, M. Giedlin, F. McCormick, and A. Fattaey. 2002. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1:325-337.
26. Khuri, F. R., J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong, and D. H. Kirn. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:879-885.
27. Kirn, D., T. Hermiston, and F. McCormick. 1998. ONYX-015: clinical data are encouraging. Nat. Med. 4:1341-1342.
28. Lee, H., J. Kim, B. Lee, J. W. Chang, J. Ahn, J. O. Park, J. Choi, C. O. Yun, B. S. Kim, and J. H. Kim. 2000. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int. J. Cancer 88:454-463.
29. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
30. Liu, G., T. J. McDonnell, R. Montes de Oca Luna, M. Kapoor, B. Mims, A. K. El-Naggar, and G. Lozano. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. USA 97:4174-4179.
31. Marin, M. C., C. A. Jost, L. A. Brooks, M. S. Irwin, J. O'Nions, J. A. Tidy, N. James, J. M. McGregor, C. A. Harwood, I. G. Yulug, K. H. Vousden, M. J. Allday, B. Gusterson, S. Ikawa, P. W. Hinds, T. Crook, and W. G. Kaelin, Jr. 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25:47-54.
32. Meyer, K. M., S. M. Hess, T. D. Tlsty, and S. A. Leadon. 1999. Hum. mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 18:5795-5805.
33. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
34. Nemunaitis, J., I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, T. Reid, S. Kaye, and D. Kirn. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60:6359-6366.
35. Nesslinger, N. J., X. B. Shi, and R. W. DeVere White. 2003. Androgenin-dependent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 63:2228-2233.
36. Nigro, J. M., K. D. Aldape, S. M. Hess, and T. D. Tlsty. 1997. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res. 57:3635-3639.
37. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
38. Ossovskaya, V. S., I. A. Mazo, M. V. Chernov, O. B. Chernova, Z. Strezoska, R. Kondratov, G. R. Stark, P. M. Chumakov, and A. V. Gudkov. 1996. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. USA 93:10309-10314.
39. Prives, C. 1994. How loops, beta sheets, and alpha helices help us to understand p53. Cell 78:543-546.
40. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126.
41. Ries, S. J., C. H. Brandts, A. S. Chung, C. H. Biederer, B. C. Hann, E. M. Lipner, F. McCormick, and W. M. Korn. 2000. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6:1128-1133.
42. Rothmann, T., A. Hengstermann, N. J. Whitaker, M. Scheffner, and H. zur Hausen. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478.
43. Schwartz, D., and V. Rotter. 1998. p53-dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol. 8:325-336.
44. Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671-680.
45. Sherr, C. J. 2001. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:731-737.
46. Steegenga, W. T., N. Riteco, and J. L. Bos. 1999. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and ΔE1B adenovirus replication in human cells. Oncogene 18:5032-5043.
47. Turnell, A. S., R. J. Grand, and P. H. Gallimore. 1999. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:2074-2083.
48. Vousden, K. H. 2000. p53: death star. Cell 103:691-694.
49. Wolf, D., N. Harris, and V. Rotter. 1984. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38:119-126.
50. Yang, C. T., L. You, C. C. Yeh, J. W. Chang, F. Zhang, F. McCormick, and D. M. Jablons. 2000. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. 92:636-641.